Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 27;46(9):9415-9429.
doi: 10.3390/cimb46090558.

A Theoretical Study of the Interaction of PARP-1 with Natural and Synthetic Inhibitors: Advances in the Therapy of Triple-Negative Breast Cancer

Affiliations

A Theoretical Study of the Interaction of PARP-1 with Natural and Synthetic Inhibitors: Advances in the Therapy of Triple-Negative Breast Cancer

Albert Gabriel Turpo-Peqqueña et al. Curr Issues Mol Biol. .

Abstract

In the current study, we have investigated the secondary metabolites present in ethnomedical plants used for medicinal purposes-Astilbe chinensis (EK1), Scutellaria barbata D. Don (EK2), Uncaria rhynchophylla (EK3), Fallugia paradoxa (EK4), and Curcuma zedoaria (Christm.) Thread (EK5)-and we have compared them with five compounds of synthetic origin for the inhibition of PARP-1, which is linked to abnormal DNA replication, generating carcinogenic cells. We have studied these interactions through molecular dynamics simulations of each interacting system under physiological conditions (pH, temperature, and pressure) and determined that the compounds of natural origin have a capacity to inhibit PARP-1 (Poly(ADP-ribose) Polymerase 1) in all the cases inspected in this investigation. However, it is essential to mention that their interaction energy is relatively lower compared to that of compounds of synthetic origin. Given that binding energy is mandatory for the generation of a scale or classification of which is the best interacting agent, we can say that we assume that compounds of natural origin, having a complexation affinity with PARP-1, induce cell apoptosis, a potential route for the prevention of the proliferation of carcinogenic cells.

Keywords: PARP-1; docking; molecular dynamics simulation; molecular mechanics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Structure of the PARP-1 protein obtained from the PDB server, ID: 4DQY.
Figure 2
Figure 2
Initial secondary structure of PARP-1 (ID: 4DQY), without additional structural agents used for crystallization.
Figure 3
Figure 3
Analysis of structural parameters RMSD, RMSF, and Rg of PARP-1 after 500 ns of molecular dynamics simulation.
Figure 4
Figure 4
Ramachandran diagram analysis of PAR-$ after the 500 ns simulation.
Figure 5
Figure 5
Two-dimensional structure of inhibitors of synthetic origin.
Figure 6
Figure 6
Two-dimensional structure of inhibitors of natural origin.
Figure 7
Figure 7
(a) Final structure of the PARP-1—DK1 coupled system after conducting a molecular dynamics simulation. (b) LigPlot diagram of the interaction.
Figure 8
Figure 8
(a) Final structure of the PARP-1—EK2 coupled system after conducting a molecular dynamics simulation. (b) LigPlot diagram of the interaction.
Figure 9
Figure 9
RMSD for the tnteraction of PARP-1 with synthetic origin compounds.
Figure 10
Figure 10
RMSD for the interaction of PARP-1 with natural origin compounds.
Figure 11
Figure 11
Ramachandran plots showing the conformational states of PARP$$ when interacting with different compounds. (a) Interaction with DK1. (b) Interaction with EK2.

Similar articles

References

    1. Ramos Águila Y.d.l.C., Marimón Torres E.R., Crespo González C., Junco Sena B., Valiente Morejón W. Cáncer de mama, su caracterización epidemiológica. Rev. De Cienc. Médicas De Pinar Del Río. 2015;19:619–629.
    1. Vallejos-Sologuren C.S. Situación del Cáncer en el Perú. Diagnóstico. 2020;59:77–85. doi: 10.33734/diagnostico.v59i2.221. - DOI
    1. Richard I.A., Burgess J.T., O’Byrne K.J., Bolderson E. Beyond PARP1: The Potential of Other Members of the Poly(ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics. Front. Cell Dev. Biol. 2022;9:801200. doi: 10.3389/fcell.2021.801200. - DOI - PMC - PubMed
    1. Quiñonero Muñoz F.J. Ph.D. Thesis. Universidad de Granada; Granada, Spain: 2023. Estudio de PARP-1 en Células Tumorales y Células Madre de Cáncer de Páncreas. Implicación en la Resistencia Tumoral y uso Como Diana Terapéutica.
    1. Torre L.A., Siegel R.L., Ward E.M., Jemal A. Global Cancer Incidence and Mortality Rates and Trends—An Update. Cancer Epidemiol. Biomarkers Amp; Prev. 2016;25:16–27. doi: 10.1158/1055-9965.EPI-15-0578. - DOI - PubMed

LinkOut - more resources